BCAB
HEALTHCAREBioAtla Inc
$4.50+0.12 (+2.74%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BCAB Today?
No stock-specific AI insight has been generated for BCAB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.92$71.50
$4.50
Fundamentals
Market Cap$7M
P/E Ratio—
EPS$-50.50
Dividend Yield—
Dividend / Share—
ROE-8.1%
Profit Margin—
Debt / Equity—
Trading
Volume21K
Avg Volume (10D)—
Shares Outstanding1.7M
BCAB News
18 articles- BioAtla Announces Share ConsolidationYahoo Finance·Mar 31, 2026
- BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsYahoo Finance·Mar 31, 2026
- BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize AssetsYahoo Finance·Mar 2, 2026
- BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)Yahoo Finance·Dec 31, 2025
- BioAtla Enters into Agreements for up to $22.5 Million Flexible FinancingYahoo Finance·Nov 21, 2025
- BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ...Yahoo Finance·Nov 14, 2025
- BioAtla (BCAB) Q3 2025 Earnings Call TranscriptMotley Fool·Nov 13, 2025
- BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent ProgressYahoo Finance·Nov 13, 2025
- BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue SarcomasYahoo Finance·Nov 7, 2025
- BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025Yahoo Finance·Nov 5, 2025
- BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus SocietyYahoo Finance·Oct 23, 2025
- BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025Yahoo Finance·Oct 3, 2025
- BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDAYahoo Finance·Sep 8, 2025
- BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent ProgressYahoo Finance·Aug 7, 2025
- BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025Yahoo Finance·Aug 4, 2025
- BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia MeetingYahoo Finance·Jul 17, 2025
- BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers CongressYahoo Finance·Jul 3, 2025
- BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimenYahoo Finance·Jun 2, 2025
All 18 articles loaded
Price Data
Open$4.82
Previous Close$4.38
Day High$4.82
Day Low$4.30
52 Week High$71.50
52 Week Low$3.92
52-Week Range
$3.92$71.50
$4.50
Fundamentals
Market Cap$7M
P/E Ratio—
EPS$-50.50
Dividend Yield—
Dividend / Share—
ROE-8.1%
Profit Margin—
Debt / Equity—
Trading
Volume21K
Avg Volume (10D)—
Shares Outstanding1.7M
About BioAtla Inc
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapies for the treatment of various cancers. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—